Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/bmjopen-2015-007651 http://scihub22266oqcxt.onion/10.1136/bmjopen-2015-007651 C4480029!4480029!26109117     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       BMJ+Open 2015 ; 5 (6): ä Nephropedia Template TP {{tp|p=26109117|t=2015. Randomised controlled trial of topical kanuka honey for the treatment of rosacea |pdf=|usr=}}{{26109117}} gab.com Text Randomised controlled trial of topical kanuka honey for the treatment of rosacea JO: BMJ Open http://www.kidney.de/pget.php?&tw=1&pmid=26109117 #FOAvip Objective: To investigate the efficacy of topical 90% medical-grade kanuka honey and 10% glycerine (Honevo) as a treatment for rosacea. Design: Randomised controlled trial with blinded assessment of primary outcome variable. Setting: Outpatient primary healthcare population from 5 New Zealand sites. Participants: 138 adults aged ?16, with a diagnosis of rosacea, and a baseline blinded Investigator Global Assessment of Rosacea Severity Score (IGA-RSS) of ?2. 69 participants were randomised to each treatment arm. 1 participant was excluded from the Honevo group, and 7 and 15 participants withdrew from the Honevo and control groups, respectively. Interventions: Participants were randomly allocated 1:1 to Honevo or control cream (Cetomacrogol), applied twice daily for 8?weeks. Main outcome measures: The primary outcome measure was the proportion of participants who had a ?2 improvement in the 7-point IGA-RSS at week 8 compared to baseline. Secondary outcomes included change in IGA-RSS and subject-rated visual analogue score of change in severity (VAS-CS) on a 100?mm scale (0?mm ?much worse?, 100?mm ?much improved?) at weeks 2 and 8. Results: 24/68 (34.3%) in the Honevo group and 12/69 (17.4%) in the control group had a ?2 improvement in IGA-RSS at week 8 compared to baseline (relative risk 2.03; 95% CI 1.11 to 3.72, p=0.020). The change in IGA-RSS for Honevo compared to control at week 2 minus baseline was ?1 (Hodges-Lehman estimate, 95% CI ?1 to 0, p=0.03), and at week 8 minus baseline was ?1 (Hodges-Lehman estimate, 95% CI ?1 to 0, p=0.005). The VAS-CS at week 2 was 9.1 (95% CI 3.5 to 14.7), p=0.002, and at week 8 was 12.3 (95% CI 5.7 to 18.9)¸ p<0.001 for Honevo compared to control. Conclusions: Honevo is an effective treatment for rosacea. Trial registration number: This trial was registered in the Australian and New Zealand Clinical Trials Registry ACTRN12614000004662. Twit Text FOAVip Randomised controlled trial of topical kanuka honey for the treatment of rosacea ????BMJ Open http://www.kidney.de/pget.php?&tw=1&pmid=26109117 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26109117 #FOAvip English Wikipedia <ref>{{Cite pmid|26109117}}</ref> Randomised controlled trial of topical kanuka honey for the treatment of rosacea #MMPMID26109117 Braithwaite I; Hunt A; Riley J; Fingleton J; Kocks J; Corin A; Helm C; Sheahan D; Tofield C; Montgomery B; Holliday M; Weatherall M; Beasley R BMJ Open 2015[]; 5 (6): ä PMID26109117show ga Objective: To investigate the efficacy of topical 90% medical-grade kanuka honey and 10% glycerine (Honevo) as a treatment for rosacea. Design: Randomised controlled trial with blinded assessment of primary outcome variable. Setting: Outpatient primary healthcare population from 5 New Zealand sites. Participants: 138 adults aged ?16, with a diagnosis of rosacea, and a baseline blinded Investigator Global Assessment of Rosacea Severity Score (IGA-RSS) of ?2. 69 participants were randomised to each treatment arm. 1 participant was excluded from the Honevo group, and 7 and 15 participants withdrew from the Honevo and control groups, respectively. Interventions: Participants were randomly allocated 1:1 to Honevo or control cream (Cetomacrogol), applied twice daily for 8?weeks. Main outcome measures: The primary outcome measure was the proportion of participants who had a ?2 improvement in the 7-point IGA-RSS at week 8 compared to baseline. Secondary outcomes included change in IGA-RSS and subject-rated visual analogue score of change in severity (VAS-CS) on a 100?mm scale (0?mm ?much worse?, 100?mm ?much improved?) at weeks 2 and 8. Results: 24/68 (34.3%) in the Honevo group and 12/69 (17.4%) in the control group had a ?2 improvement in IGA-RSS at week 8 compared to baseline (relative risk 2.03; 95% CI 1.11 to 3.72, p=0.020). The change in IGA-RSS for Honevo compared to control at week 2 minus baseline was ?1 (Hodges-Lehman estimate, 95% CI ?1 to 0, p=0.03), and at week 8 minus baseline was ?1 (Hodges-Lehman estimate, 95% CI ?1 to 0, p=0.005). The VAS-CS at week 2 was 9.1 (95% CI 3.5 to 14.7), p=0.002, and at week 8 was 12.3 (95% CI 5.7 to 18.9)¸ p<0.001 for Honevo compared to control. Conclusions: Honevo is an effective treatment for rosacea. Trial registration number: This trial was registered in the Australian and New Zealand Clinical Trials Registry ACTRN12614000004662. äRandomised controlled trial of topical kanuka honey for the treatment (epmc).pdf DeepDyve Pubget Overpricing